Structured rehabilitation nearly quadrupled weaning success in ventilated over-80s

Design

single-centre, assessor-blinded randomised controlled trial with intention-to-treat and Fine-Gray competing-risk analysis

Population

150 patients aged ≥80 years receiving prolonged mechanical ventilation, 75 per arm

Primary outcome

successful weaning from mechanical ventilation

Effect

45.3% vs 12.0%; adjusted hazard ratio 5.11 (95% CI 2.46–11.23, p<0.001); competing-risk sHR 4.45 (2.11–9.36); 90-day mortality 2.7% vs 4.0% (p=1.000)

Patients over 80 on prolonged mechanical ventilation are often written off as unweanable, and the rehabilitation they receive reflects that. This single-centre, assessor-blinded randomised trial at one Chinese hospital assigned 150 such patients, 75 per arm, to a multicomponent pulmonary rehabilitation programme or to standard rehabilitation.

Successful weaning occurred in 45.3% of the rehabilitation group and 12.0% of the standard group — an adjusted hazard ratio of 5.11 (95% CI 2.46–11.23, p<0.001), holding at 4.45 (2.11–9.36) in a Fine-Gray competing-risk analysis that accounts for death as a competing event. The intervention group was also more likely to meet prespecified improvement thresholds for oxygen saturation off the ventilator, diaphragm thickening fraction, cough strength and muscle strength at 30, 60 and 90 days, and had less ventilator-associated pneumonia at 60 and 90 days. Deep vein thrombosis did not differ, and 90-day mortality was 2.7% against 4.0%.

The effect size is unusually large for a rehabilitation trial and deserves scepticism, but the pattern supports it: diaphragm thickening fraction and cough strength are the physiological mechanisms by which weaning would improve, and both moved. Two features temper it. This is one centre, and the 90-day mortality of 2.7% to 4.0% in patients over 80 on prolonged ventilation is far lower than such cohorts usually report — so this population was selected in ways that may not match yours.

• Assess every long-term ventilated patient for a structured rehabilitation programme regardless of age; 80 is not a reason to withhold it.
• The components that moved — diaphragm function, cough strength, limb muscle strength — are what to measure and target.
• Lower ventilator-associated pneumonia at 60 and 90 days is plausible if patients are mobilising and clearing secretions, and is where much of the benefit may sit.
• This requires physiotherapy staffing over weeks, which is the real barrier in most Indian intensive care units.
• The 90-day mortality in both arms was very low for this population — check the entry criteria against your own patients before expecting this effect.

Why it matters

Age is routinely used as a reason to offer less rehabilitation to the patients in whom it made the most difference here.

Don't overread it

A single centre, with 90-day mortality far lower than typical for ventilated over-80s — the population was selected, and the effect size will not transfer intact.

The statistics, in plain English

A hazard ratio of 5.11 with an interval from 2.46 to 11.23 is a large effect with wide uncertainty, which is what 150 patients and a fourfold difference in event rates produce. The Fine-Gray analysis at 4.45 matters: with competing risks, a patient who dies cannot subsequently wean, so ignoring death can inflate the apparent benefit — that this held up is reassuring. Blinding was of the assessor only, which is unavoidable in a rehabilitation trial, and 'successful weaning' is a judgement that an unblinded clinical team makes.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.